A phase II study of anlotinib in 45 patients with relapsed small cell lung cancer

The purpose of this prospective phase II clinical trial was to investigate the efficacy and safety of anlotinib in patients with relapsed small cell lung cancer (SCLC). Forty‐five patients with relapsed SCLC were enrolled and treated with anlotinib (one cycle of 12 mg daily for 14 days, discontinued...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Int J Cancer
Main Authors: Wu, Di, Nie, Jun, Hu, Weiheng, Dai, Ling, Zhang, Jie, Chen, Xiaoling, Ma, Xiangjuan, Tian, Guangming, Han, Jindi, Han, Sen, Long, Jieran, Wang, Yang, Zhang, Ziran, Fang, Jian
Format: Artigo
Sprog:Inglês
Udgivet: John Wiley & Sons, Inc. 2020
Fag:
Cancer Therapy and Prevention
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7689882/
https://ncbi.nlm.nih.gov/pubmed/32557583
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ijc.33161
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker